Literature DB >> 15652647

Radioprotection by N-palmitoylated nonapeptide of human interleukin-1beta.

Vijay K Singh1, Venkataraman Srinivasan, Thomas M Seed, William E Jackson, Venita E Miner, K Sree Kumar.   

Abstract

Interleukin-1beta (IL-1beta) is a cytokine involved in homeostatic processes of the immune system and specifically in inflammatory reactions. The nonapeptide of human IL-1beta (VQGEESNDK, position 163-171) has been shown to retain adjuvant and immunostimulatory activities of the native molecule without any inflammatory and pyrogenic properties. A lipophilic derivative of IL-1beta nonapeptide having a palmitoyl residue at the amino terminus was synthesized in order to determine the effects of such structural modification on its bioactivities. The structurally modified peptide derivative, palmitoylated peptide, significantly protected C3H/HeN mice against potentially lethal doses of ionizing radiation. The dose reduction factor was found to be 1.07. Hematological studies show improved recovery of red blood cells and platelets in irradiated and palmitoylated peptide treated mice as compared with the untreated and irradiated group. These results suggest the importance of the derivatization of small peptides of radioprotective, but toxic cytokines in order to enhance radioprotective activity while reducing unwanted toxic side effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15652647     DOI: 10.1016/j.peptides.2004.10.022

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  2 in total

1.  Statistical analysis of survival data from radiation countermeasure experiments.

Authors:  Reid D Landes; Shelly Y Lensing; Ralph L Kodell; Martin Hauer-Jensen
Journal:  Radiat Res       Date:  2012-03-08       Impact factor: 2.841

2.  Determination of sample sizes for demonstrating efficacy of radiation countermeasures.

Authors:  Ralph L Kodell; Shelly Y Lensing; Reid D Landes; K Sree Kumar; Martin Hauer-Jensen
Journal:  Biometrics       Date:  2009-05-07       Impact factor: 2.571

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.